CFTR potentiators and correctors have been developed to correct CFTR protein dysfunction and showed impressive impact on lung function;18 these targeted therapies could be implemented in CF children with CRS to postpone pulmonary infection, particularly when P aeruginosa is present in the sinuses. Here, CFTR is linked to congenital rubella syndrome.